top of page
Recent Research
JNJ: New Imaavy faces headwinds from Myasthenia incumbents but promising in other FcRn markets
The market continues to underestimate Imaavy's prospects from...
May 21
VERA: IgAN: Atacicept phase III ORIGIN3: likely positive but Fabhalta will be hard to hurdle
Ahead of VERA’s upcoming ORGIN3 IgA nephropathy trial in 2Q25, our analysis suggests a positive Phase III outcome that is in line with its IgAN competitors. However, longer-term data from a non-BAFF/APRIL competitive class may be a hurdle...
May 15
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page